对付可怕的GT1b型丙肝，这个新药厉害了！
来源丨医学界消化肝病频道
图1：HCV基因1型是HCC发生的独立预测因子 [10]
Zepatier自问世以来，历经临床试验与实践的双重考验，积累了大量的有效证据。在今年4月召开的欧洲肝脏研究学会年会上，来自美国的Puenpatom教授团队报道的相关研究 [1]，纳入了4755例HCV感染的退伍军人，他们的生活方式具有酗酒、吸毒等特点，而且合并肝硬化、慢性肾病、糖尿病等疾病的比例也远远高于普通人群（图2）。
图:2：合并其他情况的患者比例
图3：不同丙肝类型的SVR
总结：
参考文献：
1.Abstractsof The International Liver Congress™ 2018 – 53rd annual meeting of the EuropeanAssociation for the Study of the Liver April 11–15,2018, Paris, France，JOURNAL OF HEPATOLOGY，VOLUME 68, SUPPLEMENT 1, PAGES S270.
2.Zeuzem S, Ghalib R, Reddy KR, et al.Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic andnoncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6Infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
3.George J, Burnevich E, Sheen I, et al.Efficacy and safety of elbasvir/grazoprevir in treatment-naive subjects withchronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomizedmultinational clinical trial [abstract no. 76 plus conference report].Hepatology. 2016;64(Suppl 1):41A.
4.Kwo PY, Gane E, Peng C-Y, et al.Effectiveness of elbasvir and grazoprevir combination, with or withoutribavirin, for treatment experienced patients with chronic hepatitis Cinfection. Gastroenterology.2017;152(1):164–75.
5.Rockstroh JK, Nelson M, Katlama C, etal. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) inpatients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): anon-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.
6.Hezode C, Colombo M, Bourliere M, etal. Elbasvir/grazoprevir for patients with hepatitis C virus infection andinherited blood disorders: a phase III study. Hepatology. 2017;66(3):736-745.
7.Kumada H, Suzuki F, Karino Y, et al.The combination of elbasvir and grazoprevir for the treatment of chronic HCVinfection in Japanese patients: a randomized phase II/III study. JGastroenterol. 2017;52(4):520–33.
8.Sperl J, Horvath G, Halota W, et al.Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylatedinterferon/ribavirin; a phase III randomized controlled trial. JHepatol.2016;65(6):1112–9.
9.Dore GJ, Altice F, Litwin AH, et al. Elbasvir–grazoprevir to treathepatitis C virus infection in persons receiving opioid agonist therapy: arandomized trial. Ann Intern Med. 2016;165(9):625–34.
10.Lee M-H et al. J Clin Oncol 2010;28:4587–4593.
閱讀更多 醫學界消化頻道 的文章
